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T  cells secrete a variety of hormone-like proteins or lymphokines that mediate 
many aspects  of the  immune  response.  Among  these  lymphokines are  T  cell 
growth factor or interleukin 2 (IL-2); 1 the macrophage-activating factor, immune 
or "r-interferon; and a  number of B  cell-stimulating  factors (1-3).  A  standard 
means for inducing the release of lymphokines is to stimulate rodent spleen cells 
with concanavalin A (Con A). Lymphokine release occurs over a 24-48 h period. 
By 72  h, the cultures consist of IL-2-responsive T  lymphoblasts that no longer 
release iymphokine (4). 
In this paper we studied the capacity of Con A-induced T  blasts to produce 
iymphokines as a  model for the behavior of sensitized T  cells in a cell-mediated 
immune  response.  IL-2,  immune  interferon,  B  cell-stimulating  factors,  and 
factors enhancing the development of cytotoxic T  cells were all quickly released 
over a  5-20  h  period  after the  readdition  of lectin  to  T  blasts.  Lymphokine 
secretion  required  the  induction  of new  lymphokine-specific mRNA  and  new 
protein  synthesis.  We  also  studied  the  effects of cyclosporin  A  (CSA)  in  this 
model. This immunosuppressive drug is  known to act early in several primary 
responses  (5-9),  and  was  recently  shown  to  block  the  release  of  IL-2  from 
antigen-specific T  cell blasts (10). We found that CSA blocks the production of 
many  lymphokines  and  that  this  block  is  at  the  level  of biologically  active, 
lymphokine-specific mRNA. 
Materials and  Methods 
Animals.  BALB/c mice were purchased from Charles River Breeding Laboratories, 
Inc., Wilmington, MA, and NCS mice were bred at The Rockefeller University. Xenopus 
laevis frogs were obtained from the South African Snake Farm, Fish Hoeek 7973, South 
Africa. 
Reagents.  Con A three times crystallized was purchased from Miles Laboratories, Inc., 
Elkart,  IN; 4-a-phorbol  12-myristate  13-acetate (PMA)and cycloheximide from Sigma 
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Chemical Co., St.  Louis,  MO; oligo(dT) cellulose type 77 from P-L Biochemicals, Inc., 
Milwaukee,  WI;  tissue  culture  plasticware  from  Falcon  Labware,  Oxnard,  CA;  [SH]- 
thymidine ([SH]TdR) (sp act,  17.5 Ci/mM), [sSS]methionine (sp act,  1,000  Ci/mM), and 
51Cr (sp act, 331  mCi/mg) from Schwarz/Mann Div., Becton, Dickinson & Co., Orange- 
burg, NY. CSA was a generous gift from Dr. J. F. Borel, Sandoz Ltd., Basel, Switzerland. 
A  stock  solution  of CSA  was  made  in  dimethyl  sulfoxide  (3  mg/ml)  and  diluted  in 
minimum essential medium (MEM) before each use. 
Stimulation  of Lyraphokine Release.  Con  A-activated  spleen  cells  were  prepared  as 
described elsewhere (11). Briefly, dissociated spleen cells were plated at 1.5  ×  106 cells/ 
mi in MEM containing 20 #g/ml gentamycin, 10% heat-inactivated fetal calf serum, 5 × 
10 -5 M 2-mercaptoethanol, and  1 #g/ml Con A. After 3 d, most of the viable cells were 
lymphoblasts which were then collected, washed, and plated at 2  ×  106 cells in 35-mm 
plates. The medium was 1 ml serum-free MEM containing 5 ×  10 -5 M 2-mercaptoethanol 
and 5 #g/ml Con A; to this was added  I  #g/ml CSA or 5 #g/ml cycloheximide, or, as a 
control,  solvent only.  After 2  h,  the  Con  A-induced  cell  monolayers were washed to 
remove Con A,  CSA, or cycloheximide, and  2  mi of MEM  was added.  At the desired 
time,  supernatants  for  the  bioassay  of  IL-2  or  other  lymphokines  (see  below)  were 
harvested. IL-2 was also assayed in cells that were lysed by three cycles of freezing and 
thawing. All samples were stored at -20°C prior to bioassay. EL-4 cells (5 ×  10 ~ cells/ml) 
were stimulated with PMA (10 ng/ml) in the presence or absence of CSA (1 #g/ml) again 
in serum-free medium to allow cell attachment and washing. After 2 h, cells were washed 
to  remove  PMA  and  CSA  and  were  resuspended  at  the  same concentration  in  fresh 
medium. At the desired time, supernatants and cells were harvested. Samples were stored 
at -20 °C before the bioassay for lymphokine activity. 
Isolation ofPoly(A) + RNA.  Total RNA was extracted from stimulated spleen iympho- 
10 ) using a guanidinium/cesium chloride  blasts (3-5 ×  10~) and from EL-4 cells (3-5 ×  s 
method (12,  13). Lymphoblasts were plated at 2 ×  106 cells/ml (40 ml in 150-mm culture 
plates) in MEM to which Con A (5 #g/ml) and/or CSA (1 #g/ml) was added. After 5-7 h 
incubation, cells were collected and extracted. For the preparation of RNA from EL-4, 
cultured cells (5  ×  l0  b cells/ml) were stimulated for 4 or 7 h with PMA (10 ng/ml) plus 
or minus CSA (1 #g/ml), collected, and extracted. The preparation of poly(A)  ÷ RNA was 
accomplished by batchwise fractionation using oligo(dT) cellulose. Total RNA was diluted 
in  H20 to  100  OD260 U/ml, heated at 60°C  for 2  min, and cooled quickly.  An equal 
volume of 2× HSB buffer (10 mM Tris HCI, pH 7.4, 0.12 M NaCI, 1 mM EDTA, 0.2% 
sodium dodecyl sulfate [SDS])  and prewashed oligo(dT) cellulose (1  mg cellulose for  1 
OD260 unit) were added. After the solution was shaken for 1 h at room temperature, the 
resin was washed six times with HSB and twice with HSB minus SDS, and then poly(A)  + 
RNA  was  eluted  three  times  with  H~O.  For  each  wash,  the  resin  was  collected  by 
centrifugation at 3,000 rpm for 3 min and the eluate was precipitated with 3 voi of alcohol 
after adjustment to 0.3 M NaCI. The precipitated RNA was dissolved in H20 and stored 
at -80 ° C.  100-120 #g of poly(A)  + RNA was obtained from 3 ×  106 cells. 
Translation ofPoly(A) +  RNA.  40 ng ofpoly(A)  + were injected in Xenopus laevis oocytes. 
Groups of 20 injected oocytes were incubated in microwells containing 200 #1 of Barth's 
incubation  medium  (14)  supplemented  with  bovine  serum  albumin  (0.5  mg/ml)  and 
Trasylol (50 U/ml). After 24-h intervals the medium was collected and centrifuged for 5 
min  in  an  Eppendorf microcentrifuge, and  aliquots  of supernatants  were  assayed for 
lymphokine activity. Cell-free translation of poly(A)* RNA was performed using a wheat 
germ system according to Erikson and Blobel (15). 
Biosynthetic Labeling of Lymphoblastoid Cells.  2 ×  106 blast cells were incubated for 2 h 
with  Con  A  (5  ug/ml)  and/or  CSA  (1  ug/ml)  in  1  ml  serum-free  medium  and  the 
supernatant was removed. 1 ml of MEM containing 1/20th of the usual level ofmethionine 
and 50 uCi/ml [35S]methionine (1,000 Ci/mmol) was added and the incubation continued 
for a further 20 h.  100 #1 of the resulting supernatant was mixed with sample buffer and 
applied to a  12.5% SDS-polyacrylamide gel according to Laemmli (16). 
IL-2 Assay.  IL-2 activity in conditioned medium and cell lysates were assayed on 3-d 
Con A-stimulated spleen cells as described previously (11). Serial dilutions of sample to 1794  CYCLOSPORIN  A-TREATED  T  BLASTS  LACK  LYMPHOKINE  mRNA 
be assayed were prepared in microtest wells (50 #1) to which 50 #1 of a blast suspension (4 
×  105 cells/ml) plus 20  mM a-methyl mannoside were added. After 20 h  incubation, 
microwells were pulsed with 1.7 #Ci of [SH]TdR. The cultures were harvested 4 h later 
with a  cell  harvester,  and  filters were  counted in  Liquifluor-Toluene. The  [3H]TdR 
uptakes reported are from the linear portion of the dose response curve. 
Interferon (IFN) Assay.  IFN activity in conditioned medium was determined by the 
inhibition of the cytopathic effect of vesicular stomatitis virus on the mouse fibroblast line 
L929/B. Confluent monolayers were seeded in microtest wells with threefold dilutions of 
the supernatant to be assayed. After 20 h of incubation, an infecting dose of virus was 
added. The plates were examined under the microscope to determine the last dilution of 
supernatants that inhibited the lysis of 50% of the cells. A standard for mouse IFN was 
included in each assay. CSA up to 5 #g/ml did not inhibit the bioassay. 
B cell-stimulating Factors(s) Assay.  The assay for B cell helper factor(s)  was done as 
described by Inaba et al. (17) using 3 ×  106 purified B cells as the responder and sheep 
red blood cells as antigen. In this assay the development of anti-sheep plaque-forming 
cells (PFC) required helper factor(s) and specific antigen. CSA inhibited the bioassay 50% 
at  10 ng]ml, so it was useful to use CSA-pulsed  cells to study the inhibition of helper 
factor formation. 
Cytotoxic Differentiation Factor Assay.  Murine thymocytes develop antigen-specific cy- 
totoxic T  cells when cultured with antigen and Con A supernatant (18). We adapted this 
phenomenon to a more rapid, polyclonal assay. 5 ×  105 thymocytes from Swiss or B6.H- 
2k mice (4 wk old) were suspended in MEM supplemented with 10% heat-inactivated fetal 
calf serum, 5 × 10  -~ M 2-mercaptoethanol, and 1 #g/ml Con A, and cultured in microwells 
with several  dilutions of conditioned media.  The polyclonal cytotoxic T  lymphocytes 
(CTL) response was measured after 48-72  h  using 5'Cr-labeled P815 as targets ill the 
presence of I 0 ttg/ml phytohemagglutinin (PHA). Con A supernatants were the positive 
control and mediated the development of Thy-1 ÷, Lyt-2  ÷ lytic cells that required PHA to 
exhibit lysis. Purified (11) or recombinant IL-2 (Biogen, Cambridge MA), recombinant 
1FN (Genentech, San Francisco, CA), or IL-1 (produced by the J774 macrophage cell line 
stimulated with lipopolysaccharide), singly or together, did not support a CTL response 
in this assay. 
Results 
Cycloheximide Inhibits Synthesis of IL-2 from Mitogen-restimulated  Blast Cells.  To 
study the production of lymphokine from sensitized T  cells, we prepared  lym- 
phoblasts by stimulating mouse spleen cells for 72-96  h  with the mitogen, Con 
A. Although these Con A  blasts responded to  IL-2, they did not produce this 
lymphokine (4).  In contrast, restimulation with mitogen led to the production 
and secretion of high levels of IL-2 (Fig.  1).  IL-2 activity in cell lysates and in 
the conditioned medium represented de novo synthesis because it was blocked by 
5 #g/ml cycloheximide (Fig.  1), an inhibitor of protein synthesis. 
CSA  Inhibits  Lymphokine  Production  from  Con  A-restimulated  T  Blasts.  Al- 
though CSA is regarded as an inhibitor of primary responses, CSA also inhibited 
the synthesis and release  of IL-2  from lymphoblasts restimulated  with Con A 
(Fig. 2A). In contrast, CSA did not block the proliferative response of T  cells to 
exogeneous IL-2 unless added at relatively high doses, >2 ug/ml (Fig. 2B). 
Similar findings were made when the release of other lymphokines was evalu- 
ated.  After the addition  of Con  A,  control  T  lymphoblasts quickly produced 
immune IFN, B cell-stimulating factors, and mediators needed for the develop- 
ment of CTL (Table I). Release of all lymphokines was blocked by CSA. To rule 
out an inhibitory effect of residual CSA on the lymphokine bioassays, we pulsed 
the blasts rather than continuously exposing to CSA (Methods and Materials). GRANELLI-PIPERNO,  INABA,  AND  STEINMAN  1795 
y 
/  /  "-- 
// 
" I/1 
.....  ~-  -  *  -~  ....  i-:-  -  -• 
o  2  6  I0 
FIGURE  l.  T  lymphoblasts produce  IL-2  in  response  to  mitogen  restimulation: effect  of 
cycloheximide. 3-d Con A blasts were collected and adjusted to 2 x  10  8 cell/ml in serum-free 
medium.  0.,5 m] of cells were incubated for 2  h  with or without Con A  (5 #g/ml), with or 
without cycloheximide (5 #g/ml).  After 2  h, medium was removed and replaced with  1 ml 
fresh medium. Supernatant and cells were collected at the indicated times and assayed for IL- 
2  activity.  Control  cultures:  (O--'O)  conditioned  medium,  (0.. "0)  cell  lysates.  Con  A- 
restimulated cultures: (O------O) conditioned medium, (O  O) cell lysates. Con A + cyclohex- 
imide cultures: (['-I  I-I) conditioned medium, (ll--------1) cell lysates. 
b 
x 
I 
>'0 
oo 
N  0 
-8 
.c: 
7-- 
1e  A 
V 
14  ~o 
~x 
.oE 
IG  o  UN 
~d 
c_o 
.9 
~c 
.c_ 
2 
o  g  lO  20 
(h) 
I  I  I  I 
0.3  1.25  5  20 
CSA  (JJglml) 
FIGURE 2.  T  lymphoblasts produce IL-2 in response to mitogen restimulation: effect of CSA. 
(A) 3-d Con A  blasts were collected and adjusted at 2  x  10Ocell/ml in serum-free medium. 
0.5 ml of cells were incubated for 2 h with Con A (5 #g/ml) with or without CSA (1/~g/ml) or 
left  untreated.  After  2  h,  medium  was  removed  and  replaced  with  1  ml  fresh  medium. 
Supernatants and cells were  collected at the indicated times and assayed for  IL-2 activity. 
Control cultures: (I-q) conditioned medium, (1) cell lysates. Con A-restimulated cultures: ((3) 
conditioned medium, (0) cell lysates. Con A/CSA cultures: (A) conditioned medium (A) cell 
lysates. (B) 3-d blast cells were grown in the presence of a  fixed amount of IL-2 and various 
concentrations of CSA. CSA concentrations >  2 ug/ml were required to block IL-2-mediated 
proliferation of activated T  cells. 1796  CYCLOSPORIN  A-TREATED  T  BLASTS  LACK  LYMPHOK1NE  mRNA 
TABLE  I 
Effect of Cyclosporin A on Lymphokine Release by Con A-restimulated  T Cell Blasts 
Source of supernatant and duration (h) of culture 
Lymphokine assayed  Control  Con A  Con A +  CSA 
5  10  20  5  10  20  5  10  20 
Interferon*  <4  <4  <4  30  100  300  <4  <4  <4 
B cell-stimulating fac-  0  0  0  968  2,408  2,384  0  0  160 
tor(s)  ~t 
Cytotoxic differentia-  1.3  2.2  1.7  5.4  13  31.5  1.4  3  3.6 
tion factor(s)  § 
Conditioned medium (20%) was derived from blast cells that had been cultured for 5-20 h with or 
without Con A, with or without CSA. 
* Results are expressed as interferon units. 
Results are expressed as PFC for individual cultures. 
0 Results are expressed as the percent 5~Cr released in a 4-h lectin-dependent cytotoxic assay. 
No inhibition of the bioassays was noted when we mixed the conditioned medium 
from Con A- and Con A/CSA-treated cells. 
CSA Does Not Block Other Con A-mediated Responses.  Several experiments were 
then performed which suggested that the inhibitory effect of CSA on lymphokine 
production  was  selective.  When  total  protein  synthesis  was  studied  in  [35S]- 
methionine-labeled lymphoblasts, CSA did not alter the release of TCA-precipi- 
table label or the pattern of released polypeptides, as detected by one-dimensional 
SDS-polyacrylamide gel electrophoresis (Fig.  3).  Interestingly,  the addition  of 
Con  A  produced some changes  in  the  polypeptides secreted  by lymphoblasts; 
i.e.,  some bands  were diminished  and  other  bands  induced  when  Con  A  was 
added, but none of these changes were altered by CSA (Fig. 3, arrows). CSA also 
did  not  inhibit  polyclonal  cytolytic T  cell  function,  in  which  Con  A-induced 
lymphoblasts  killed  ~lCr-labeled  targets  in  the  presence  of lectin  (Table  II). 
Lastly, CSA did not block the induction of plasminogen activator release in Con 
A-stimulated  mouse macrophages (Table II). Together these results show that 
CSA inhibits the production of a  variety of lymphokines from large T  lympho- 
cytes but does not affect the overall synthetic or killer activity of these cells, nor 
a Con A-induced response in macrophages. 
CSA  Inhibits  IL-2  Production  and  IL-2  mRNA  Synthesis  from  the  EL-4  Cell 
Line.  Previous work (19)  had  shown  that  the  thymoma  cell  line  El-4  can  be 
induced to produce IL-2 upon adequate stimulation.  While exploring the effect 
of CSA on blast cells we observed that this drug also inhibited production of IL- 
2 from EL-4 cells that were challenged  with the tumor promotor PMA (Table 
III). Unfortunately, our EL-4 cells did not release lymphokines other than IL-2. 
The availability of large numbers of EL-4 cells allowed us to examine whether 
IL-2 mRNA was induced by PMA and if the induction  of mRNA was sensitive 
to CSA.  Indeed, when  EL-4 cells were induced with  PMA, active IL-2 mRNA 
could be extracted and translated in oocytes (Table IV), confirming the work of 
Bleackley et al. (20). When we injected mRNA from CSA-inhibited, PMA-treated 
EL-4 cells, no IL-2 was detectable in the medium conditioned by oocytes. 
Effect  of CSA  on  the  Induction  of Biologically  Active  Lymphokine  mRNA.  We GRANELLI-PIPERNO,  INABA,  AND  STEINMAN  1797 
FIGURE 3.  Autoradiogram  of SDS-PAGE of biosynthetically labeled  cultures  of mitogen- 
restimulated T  blasts.  3-d  Con A  blasts  were collected and adjusted  to  2  ×  106  cell/ml in 
serum-free medium. 0.5 ml cells were incubated for 2 h without Con A or with 5 #g]ml Con 
A, or with  Con  A  +  1 #g/ml  CSA.  After 2  h,  medium  was  removed and  1  ml  medium 
containing  [35S]methionine  (50 #Ci/ml)  was  added  to  the cultures.  After  18  h  incubation, 
supernatants were analyzed in a  12.5% SDS-polyacrylamide gel. (A) Control cultures, (B) Con 
A-treated cultures,  (C)  Con  A/CSA-treated cultures.  Arrows indicate changes  in  secreted 
polypeptides that occur when Con A is added. This experiment was repeated usihg spleen cells 
that were depleted of B cells with anti-lg and complement before Con A stimulation Compa- 
rable results were obtained. 
TABLE  II 
Con A Responses That Are Not Inhibited  by CSA 
-CSA  +CSA 
-Con A  +Con A  -Con A  +Con A 
Total protein synthesis*  20.424  35.241  19.430  32.137 
Cytolytic activity*  3.1  48  2.8  49 
Release of plasminogen activator  !  5  29.5  4.7  28.8 
* Blast cells (2  x  106) were restimulated with or without Con A, with or without CSA, in medium 
containing  50  #Ci/ml  [sSS]methionine  for  20  h.  TCA-insoluble radioactivity  was  measured  in 
aliquots of supernatants. 
* Blast cells were tested for their capacity to lyse ~Cr-labeled P815 targets in a 4-h lectin (Con A)- 
dependent cytotoxic assay in the presence or absence of CSA (1 #g/ml). 
§  6  Peritoneal macrophages (3 ×  10 ) were treated with or without 5 t~g/ml Con A, with or without 1 
~g/ml CSA in serum-free medium for 20  h.  Supernatants  were collected and  25  #1 assayed  for 
enzyme activity (27).  Results are expressed as the percent of 125I-fibrin solubilized. 
proceeded to look at the effects of CSA on the induction of lymphokine mRNA 
from primary T  lymphoblasts. RNA was extracted from blast cells or from blast 
cells restimulated  for 5  h  with Con  A  in the presence or absence of CSA.  We 
then  assayed  lymphokines  in  conditioned  media  from  cultured Xenopus laevis 
oocytes that had been injected with these RNA preparations. 
First,  we established that  restimulation  of T  blasts led to the appearance  of 
mRNA for several lymphokines. Xenopus oocytes were microinjected with 40 ng 
of RNA from either Con A-restimulated or unstimulated cultures. After 24-48 
h  of incubation,  the  oocyte incubation  medium  was  assayed  for  lymphokine 
biological  activity  (Table  V).  IL-2,  3,-IFN,  B  cell-stimulating  factor(s),  and 1798  CYCLOSPORIN  A-TREATED  T  BLASTS  LACK  LYMPHOKINE  mRNA 
TABLE  III 
Effect of CSA on IL-2 Release  from PMA-stimulated EL-4 
[SH]TdR incorporated after 7 or 20 h 
culture of: 
Stimulation  Cell extracts  Conditioned 
medium 
7  20  7  20 
None  1,426  1,450  1,817  1,242 
EL-4 +  PMA  51,050  94,687  65,200  251,228 
EL-4 +  PMA +  CSA  2,291  1,613  1,713  3,073 
Conditioned medium (10 #1) and cell extracts (20 #1) were derived from 
EL-4 stimulated with PMA (10 ng/ml) in the presence or absence of CSA 
(1 ttg/ml) for 7 or 20 h. Data are cpm [SH]TdR incorporated in an IL-2 
assay. 
TABLE  IV 
Translation  in Xenopus laevis Oocytes of EL-4 mRNA: Effect of CSA 
on IL-2 Activity 
IL-2 activity 
Source of mRNA  ([3H]TdR cpm) 
None  1,350 
EL-4  1,210 
EL-4 +  PMA (4 h)  15,070 
EL-4 +  PMA (7 h)  29,807 
EL-4 +  PMA +  CSA (4 h)  1,870 
EL-4 +  PMA +  CSA (7 h)  1,083 
Conditioned medium was derived from groups of oocytes microinjected 
with 40 ng mRNA from EL-4 cells that were PMA induced (10 ng]ml) or 
not induced (4 or 7 h), in the presence or absence of CSA (1 #g/ml). The 
equivalent of medium conditioned by 2.5 oocytes was assayed for IL-2. 
TABLE  V 
Translation  in Xenopus laevis Oocytes of mRNA from Mitogen-activated T Cell Blasts: Effect of 
CSA 
Source of mRNA and duration (h) of culture 
Lymphokine assayed  Control  Con A  Con A +  CSA 
24  48  24  48  24  48 
IL-2*  1,159  1,254  12,523  4,319  1,290  1,169 
Interferon*  <4  <4  300  1,000  <4  10 
B cell-stimulating factor(s)  j  0  0  38  240  0  3 
Cytotoxic differentiation  1  1.4  9.3  11.2  1.1  1.5 
factor(s)  ! 
Conditioned medium from groups of oocytes cultured 24 or 48 h, after microinjection of 40 ng 
mRNA, was assayed. The mRNA was from control blasts or blasts restimulated with Con A with 
or without CSA  for 5  h. The equivalent of medium conditioned by 2.5  oocytes was assayed for 
lymphokine activity. 
* Results are expressed as [SH]TdR cpm incorporated. 
* Results are expressed as interferon units. 
0 Results are expressed as PFC for individual cultures. 
! Results are expressed as the percent 51Cr released in a 4-h lectin-dependent cytotoxic assay. GRANELLI-PIPERNO,  INABA,  AND  STEINMAN  1799 
FIGURE 4.  Autoradiogram of SDS-PAGE of translation products of activated T  cell mRNA. 
Poly(A)  ÷ RNA (5 #g) extracted from control blast cells (A), Con A-treated blasts (B), or Con 
A/CSA-treated blasts (C) were translated in a cell-free system. Aliquots of translation products 
were analyzed in a 6-15% SDS-polyacrylamide gel, 
cytotoxic  differentiation  factor(s)  activities  were  detectable,  but  only  in  the 
medium conditioned by oocytes that had received poly(A)  + RNA from mitogen- 
restimulated cultures vs. control blasts. 
When mRNA was isolated from T  blasts restimulated in the presence of CSA, 
no  detectable  lymphokine activity  was  found  in  the  conditioned  medium of 
oocytes (Table V). Therefore, CSA blocks the induction of active lymphokine 
mRNA. 
To analyze if CSA and Con A would alter the levels of mRNA for bulk cellular 
proteins,  we  translated  mRNA  from control,  and  Con  A-  and  Con  A/CSA- 
restimulated blasts in a cell-free system. The pattern of synthesized proteins was 
very similar using each of the three sources of mRNA (Fig. 4). This suggests that 
the effects of Con A and CSA on lymphokine mRNA are selective. 
Discussion 
Lymphokine Release  from T Lymphoblasts.  T  lymphoblasts that have been acti- 
vated for 3 d  with the mitogen Con A  do not produce or secrete lymphokines 
constitutively. Instead,  lymphokine release requires restimulation with Con  A 
(4). This conclusion applies to a large group of lymphokines, including IL-2, 7- 
IFN, and B cell- and CTL-stimulating factors (Fig.  1, Table I). 
Induction  of lymphokine synthesis can  be  attributed  to  the  appearance  of 
biologically active lymphokine mRNA. Within a few hours of restimulation, IL- 
2  mRNA appeared and  this  induction corresponds well with the  increase of 
lymphokine seen in cell extracts and the conditioned medium. The effect was 1800  CYCLOSPORIN  A-TREATED  T  BLASTS  LACK  LYMPHOKINE  mRNA 
not limited to IL-2 mRNA, since we succeeded in detecting active mRNAs for 
3,-IFN as well as B cell- and CTL-stimulating factors (Table V). 
If one considers the Con A blast as a model for a sensitized T  cell generated 
during an immune response, then these sensitized cells are exquisitely dependent 
upon restimulation for the release of lymphokine. It appears  that there is no 
constitutive  release  or  protein  stores  of these  important  mediators.  Cellular 
immune responses involve the emigration of large numbers of T  blasts into the 
efferent lymph (21,  22).  Presumably the blasts emigrate to inflammatory sites 
where antigen must be encountered for lymphokine mRNA and protein synthesis 
to be induced. 
Effects of CSA on Lymphokine Release.  A substantial body of data demonstrates 
the immunosuppressive properties of the fungal metabolite, CSA. Several T  cell 
responses, such as the mixed leukocyte reaction, lectin mitogenesis, and delayed 
hypersensitivity, are blocked when the drug is given early in the response (5-9, 
23, 24). Our data indicate that CSA inhibits lymphokine release from preformed 
T  blasts by blocking the induction of active lymphokine mRNA. The inhibition 
applies  to a  variety of lymphokines (Table V), but not to mRNA's mediating 
bulk protein synthesis (Fig.  4).  Also, CSA did not block several other Con A- 
stimulated events, such as the overall increase in cell protein synthesis that occurs 
with Con A, and some changes in the pattern of polypeptides that are induced 
by lectin (Table II and Fig. 3). 
CSA inhibited EL-4 cells similarly to Con A blasts (Tables III and IV). With 
EL-4, PMA was used to induce active IL-2 mRNA. These data indicate that CSA 
selectively blocks the expression of lymphokine mRNA in  response to several 
stimuli. 
The mechanism by which CSA inhibits lymphokine mRNA is not yet clear. It 
is possible that CSA directly interferes with the transcription of new lymphokine 
mRNA, or the drug could alter the function of other products that are essential 
for the expression of active message. Analysis with cloned probes will resolve this 
point. 
CSA  is  being  used  clinically  to  suppress  the  immune  response  to  organ 
transplants. The drug must be given early, possibly to prevent the development 
of CTL, since CTL function seems not to be sensitive to CSA (Table II). Our 
data  suggest  that  CSA  also  may  be  useful  in  suppressing  T  cell-mediated 
responses that  require lymphokine release,  including responses by T  lympho- 
blasts. For example, CSA blocks the expression of delayed-type hypersensitivity 
in  antigen-primed  animals  (23,  24)  and  this  block  could  be  at  the  level  of 
lymphokine release. Also, tissue damage in diseases like rheumatoid arthritis or 
sarcoidosis may be mediated by the production of lymphokines by sensitized T 
cells present in joints or lungs (25, 26). CSA might be an effective immunosup- 
pressive agent during active disease. 
Summary 
Three-day, concanavalin A-induced T lymphoblasts have been used as a model 
to  study lymphokine release from sensitized T  cells.  The blasts  responded to 
interleukin 2 (IL-2) but did not constitutively produce this or other lymphokines. 
After mitogen restimulation, blast cells synthesized IL-2 as well as v-interferon, GRANELLI-PIPERNO, INABA, AND  STEINMAN  1801 
B cell-stimulating factor(s), and cytolytic differentiation factor(s). This produc- 
tion resulted from the induction of biologically active lymphokine mRNA. 
Cyclosporin A  (CSA), a  potent immunosuppressive agent, strongly inhibited 
synthesis of IL-2, ~'-interferon, and B cell- and CTL-stimulating factor(s), from 
mitogen-restimulated  T  blasts.  In  contrast,  CSA  did  not  block  the  cytolytic 
activity of the T  blasts,  nor modify bulk protein synthesis induced by Con A. 
CSA also blocked lymphokine release from a  phorbol myristate acetate-stimu- 
lated thymoma cell line, EL-4. The effect of CSA was to block the induction of 
active  lymphokine  mRNA,  as  assayed  in  an  oocyte  translation  system.  This 
selective inhibition of lymphokine mRNA suggests that CSA may be useful in 
the therapy of inflammatory, lymphokine-mediated disease states. 
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Note added in proof" While this article was in press, Kr6nke et al. (Proc. Natl. Acad. Sci. USA, 1984, 
81:5214) published results demonstrating that CSA inhibits IL-2 gene expression at the level of 
mRNA transcription in the human leukemic T cell line Jurkat. 
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